Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Chinese Academy of Sciences

Chongqing Shangjia Electronic Co., Ltd.

Chongqing University

Chongqing Fochon Pharmaceutical Co., Ltd.

Fochon Biosciences, Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Weipeng Zhang

Weibo Wang

Xingdong Zhao

Haohan Tan

Rui Tan

Jing Sun

Zhifu Li

Hongbin Liu

Huajie Zhang

Xianlong Wang

Tongshuang Li

Yanxin Liu

Zhifang Chen

Ling Chen

Qihong Liu

Qiang Tian

Min Lin

Bin Liu

Jian Ding

Meiyu Geng

Zuwen Zhou

Jing Ai

Lihua Jiang

Xia Peng

Yue Rong

Lijun Yang

Ping Li

Chengxi He

Zongyao Zou

Xinren Liao

Shu Lin

Juncai Ma

Liang Fu

Shuchun Li

Zhan Xu

Yunling Wang

FuSheng Pan

Li Linghu

Kai Ran

Yuwei Gao

Tao Cheng

Hualin Xie

Chuiliang Yu

Hong Fu

Provided is a method for preparing a soft magnetic manganese-zinc ferrite composite by removing impurities from industrial waste step by step. Manganese-containing waste residue is crushed and dried, and then mixed with a flux in a muffle furnace and roasted at a temperature below 1000° C. till solid-liquid stratification; then, multi-step impurity removal is performed to obtain a high-purity quaternary purification solution of manganese sulfate. Similarly, zinc residue is melted to remove impurities, and then multi-step impurity removal is performed to obtain a high-purity quaternary purification solution of zinc sulfate. According to a manganese-zinc-iron ratio required for the manganese-zinc ferrite, the two purification solutions are mixed, and ferrous sulfate is added. The mixed purification solution is coprecipitated with ammonium bicarbonate, washing is performed, and co-precipitated powder is decomposed into ferric oxide, manganese tetroxide and zinc oxide which are then roasted to obtain the manganese-zinc ferrite composite.

Method for preparing soft magnetic manganese-zinc ferrite composite by removing impurities from industrial waste step by step

A method for synchronous production of manganese tetraoxide and ferric oxide for a soft magnetic material by using marine polymetallic nodules includes: 1) crushing and grinding marine manganese nodules and baking to a constant weight; thoroughly mixing with a mixed flux and roasting in a muffle furnace; 2) carrying out solid-liquid separation, washing solid-phase precipitates with water, grinding the solid, adding sulfuric acid, controlling the temperature to be below 50&#xb0; C., and vacuuming a reactor up; 3) adding a reducing agent to react at room temperature for 5-10 min, adding ammonia water to adjust the pH value to 5.5, and carrying out separation and filtering; 4) controlling the temperatures of manganese sulfate and ferric sulfate solutions to be below 50&#xb0; C., and adding ammonium sulfide; and 5) washing with deionized water, and calcining at 800-900&#xb0; C. for 1-3 s by a suspension low-temperature instantaneous firing system.

Method for synchronous production of manganese tetraoxide and ferric oxide for soft magnetic material by using marine polymetallic nodules

Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Macrocyclic compounds as TRK kinases inhibitors

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK. 

Deuterated compounds as rock inhibitors

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Certain protein kinase inhibitors

Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Growing community of inventors

Chongqing, China

Weipeng Zhang